Johnson & Johnson CEO Joaquin Duato Joins $30 Million Club with 30% Pay Hike in 2025

As more and more pharmaceutical companies announce CEO compensation for 2025, another top executive from a large pharmaceutical company has joined the ranks.$30 Million Club。

Johnson & Johnson CEODu Anqing (Joaquin Duato）Total Compensation for 2025 is Nearly$32.8 million, compared to 2024$24.3 millionSignificant Leap.

Du Anqing is a holder of dual nationality, American and Spanish,Holds an MBA degree from ESADE Business School in Spain and a Master's degree in International Management from Thunderbird School of Global Management in the United States.Currently serves as Vice Chairman of the Executive Committee, Chairman of the Board, and Chief Executive Officer of Johnson & Johnson.

In January 2015, Du Anqing obtained U.S. citizenship.

Du AnqingIn 2009, he became the Chairman of Johnson & Johnson's pharmaceutical group in the Americas. Starting from 2011, he served as the global chairman of the pharmaceutical business, leading the global transformation of this business and promoting the launch of 16 new drugs. In January 2022, after taking over as the CEO of Johnson & Johnson, he proposed a strategic focus on medical technology mergers and acquisitions.In 2022,Du AnqingOfficially appointed as CEO of Johnson & Johnson.

In terms of specific salary structure: Du AnqingThe base salary is $1.6 million, remaining the same as in 2024; additionally obtainedNearly $21 million in stock and option awards, non-equity incentive compensation during the same period is approximately$4.3 million。Other CompensationTotal project approximately$600,000Some companies will include travel, security, and other related expenses in this category, but Johnson & Johnson clearly states in its compensation report: such expenses are accounted for separately.Not included in executive compensation。

In addition, due to Du AnqingThePension Value and Deferred Compensation BenefitsThe accounting method has been adjusted, and the project will reach its target in the 2025 fiscal year.$5.3 million。

Du AnqingSalary in 2025 compared to 2024An increase of approximately 30%, the reason given by the Johnson & Johnson Board is:The company exceeded its strategic and financial goals for 2025, thus triggering the CEO's annual performance bonus.118.3% of the target value, Long-term incentives achieved145% of the target value。

The board also affirmedDu AnqingIn the company's responsePatent Expiration for Autoimmune Drug StelaraThe Role in Major Challenges and Praise for Its 2025 Business Expansion Initiatives and R&D Pipeline Management.

Du Anqing has high hopes for the company's future. Johnson & Johnson earlier this year forecasted sales to reach $100 billion to $101 billion by 2026., and expressed optimism about achieving it by the end of this decade.Double-digit revenue growth。Du AnqingReferred to 2025 as the company's "Leap Year" in the recent earnings call.: Sales growth reached 6% for the year in China$94.2 billion

As Stelara faces generic drug competition, Johnson & Johnson's current main cash cow is a multiple myeloma drug.Darzalex, the drug's sales in 2025 are close to$14.4 billion, a significant increase compared to 202423%。

At the same time, the sales of Johnson & Johnson's drugs such as Tremfya, Spravato, and CAR-T product Carvykti continue to break through.$10 billionThreshold.

Du Anqing told analysts at the earnings release in January: "We are different from other companies. We do not rely on one or two growth drivers."。”

Compiled from: fiercebiotech